[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646522":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":40,"centralContacts":60,"locations":66,"responsibleParty":84,"collaborators":40,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":40,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":40,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":40,"overallStatus":105,"whyStopped":40,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",[8,13,16,19,23,26,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose 1","EXPERIMENTAL","Drug: HRS-4729 Injection",[11],{"label":14,"type":10,"description":11,"interventionNames":15},"Dose 2",[11],{"label":17,"type":10,"description":11,"interventionNames":18},"Dose 3",[11],{"label":20,"type":10,"description":11,"interventionNames":21},"Dose 4",[22],"Drug: HRS-4729 Injection;",{"label":24,"type":10,"description":11,"interventionNames":25},"Dose 5",[22],{"label":27,"type":10,"description":11,"interventionNames":28},"Dose 6",[22],{"label":30,"type":31,"description":32,"interventionNames":33},"Placebo","PLACEBO_COMPARATOR","Drug: HRS-4729 Injection Placebo",[32],[35,41,44,47,51,54,57],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","HRS-4729 Injection","HRS-4729 Injection; Dose 1",[9],null,{"type":36,"name":37,"description":42,"armGroupLabels":43,"otherNames":40},"HRS-4729 Injection; Dose 2",[14],{"type":36,"name":37,"description":45,"armGroupLabels":46,"otherNames":40},"HRS-4729 Injection; Dose 3",[17],{"type":36,"name":48,"description":49,"armGroupLabels":50,"otherNames":40},"HRS-4729 Injection;","HRS-4729 Injection; Dose 4",[20],{"type":36,"name":48,"description":52,"armGroupLabels":53,"otherNames":40},"HRS-4729 Injection; Dose 5",[24],{"type":36,"name":48,"description":55,"armGroupLabels":56,"otherNames":40},"HRS-4729 Injection; Dose 6",[27],{"type":36,"name":58,"description":58,"armGroupLabels":59,"otherNames":40},"HRS-4729 Injection Placebo",[30],[61],{"name":62,"role":63,"phone":64,"phoneExt":40,"email":65},"Ziwei Du","CONTACT","+86 0518-81220121","ziwei.du.zd9@hengrui.com",[67],{"facility":68,"status":40,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality","200025","China","CN",{"type":75,"coordinates":76},"Point",[77,78],121.45806,31.22222,{"lat":78,"lon":77},[81],{"name":82,"role":83,"phone":40,"phoneExt":40,"email":40},"Weiqing Wang","PRINCIPAL_INVESTIGATOR",{"type":85,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100646522","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-hrs-4729-injection-in-obesity-100646522",false,"NCT07690826","A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity","A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Participants With Obesity","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent.\n2. Male or female adults aged 18 to 65 years.\n3. BMI: 28.0 to 40.0 kg\u002Fm2.\n4. Self-reported diet and exercise control for at least 3 months before screening, with body weight change of no more than 5 kg during the previous 3 months.\n\nExclusion Criteria:\n\n1. Endocrine disease or history that may have a significant effect on body weight;\n2. History of diabetes mellitus (gestational diabetes excepted);\n3. Malignancy of any organ system within the past 5 years, irrespective of evidence of local recurrence or metastasis, except for adequately treated localized basal cell carcinoma of the skin, carcinoma in situ of the cervix, and prostate carcinoma in situ;\n4. Presence or suspicion of depression, anxiety disorder, bipolar disorder, suicidal ideation, schizophrenia, or other clinically significant psychiatric disorder, or a history of suicide attempt;\n5. Known or suspected excessive alcohol use, or a history of alcohol, drug, or substance abuse;\n6. Acute or chronic hepatitis, or a history of severe hepatic disease other than metabolic dysfunction-associated fatty liver disease;\n7. Prior or planned organ or bone marrow transplantation during the study period;\n8. Any hematologic disorder that may interfere with the determination of HbA1c;\n9. An autoimmune disease for which systemic corticosteroid or immunosuppressive therapy is planned during the study period;\n10. Use of any medication or treatment likely to cause clinically significant weight gain or weight loss within 3 months prior to screening;\n11. Participation in any clinical trial of an investigational drug or medical device within 3 months prior to screening;\n12. Blood donation or blood loss ≥400 mL, or receipt of a blood transfusion, within 3 months prior to screening;\n13. Mental incapacity or language impairment sufficient to preclude adequate understanding of, or participation in, the trial procedures;\n14. Investigators, site staff, or other personnel directly involved in conduct of the study, and their immediate family members; employees of the Sponsor;\n15. Any condition that, in the investigator's judgment, would compromise participant safety or otherwise interfere with the assessment of study results.","ALL","18 Years","65 Years",{"count":97,"type":98},252,"ESTIMATED","INTERVENTIONAL",[101],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.",[104],"Overweight or Obesity","NOT_YET_RECRUITING","2026-07-01",{"date":108,"type":109},"2026-07-08","ACTUAL",{"date":111,"type":98},"2026-07",{"date":113,"type":98},"2027-07",{"name":5,"class":6},1]